missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human CD11c Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 5 publications
Brand: R&D Systems MAB1777-SP
This item is not returnable.
View return policy
Description
CD11c Monoclonal specifically detects CD11c in Human samples. It is validated for Flow Cytometry, Immunoprecipitation, CyTOF-ready.
Specifications
| CD11c | |
| Monoclonal | |
| LYOPH | |
| Flow Cytometry 2.5 ug/10^6 cells, Immunoprecipitation, CyTOF-ready | |
| 95, 95 alpha chain, 95, alpha subunit, CD11 antigen-like family member C, CD11c, CD11c antigen, CD11Cleu M5, alpha subunit, Integrin alpha X, integrin alpha-X, integrin, alpha X (antigen CD11C (p150), alpha polypeptide), integrin, alpha X (complement component 3 receptor 4 subunit), ITGAX, Leu M5, Leukocyte adhesion glycoprotein p150, Leukocyte adhesion receptor p150, leukocyte surface antigen p150, myeloid membrane antigen, alpha subunit, p150 95 integrin alpha chain, p150,95 alpha, SLEB6 | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 3687 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG1 |
| Flow Cytometry, Immunoprecipitation, CyTOF | |
| ICRF 3.9 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| CD11c | |
| Rheumatoid synovial fluid cells and human monocyte-derived fibronectin | |
| 25 μg | |
| Primary | |
| Detects human CD11c. | |
| Human | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction